Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present U.S. Stem Cell, Inc. (OTC: USRM).

Full DD Report for USRM

You must become a subscriber to view this report.


Recent News from (OTC: USRM)

U.S. Stem Cell reports Q2 results
U.S. Stem Cell ( OTCQB:USRM ): Q2 EPS of $0.00 More news on: U.S. Stem Cell, Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 08 2018 17:18
USRM Posts Profitable Results for Second Quarter 2018
SUNRISE, Fla. , Aug. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced results for its second quarter in 2018 -- the 10th consecutive qua...
Source: PR Newswire
Date: August, 08 2018 16:30
Stem Cells Shows Promise For Repairing Torn Meniscus
SUNRISE, Fla. , July 10, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has demonstrated successful, in-human results in repai...
Source: PR Newswire
Date: July, 10 2018 08:30
'Renewing Our Heroes' to Provide USRM Stem Cell Protocol to First Responders
SUNRISE, Fla. , June 5, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Renewing Our Heroes   -- a charitable health initiative esta...
Source: PR Newswire
Date: June, 05 2018 08:00
USRM Chief Science Officer to Present at Fifth Annual Cell Surgical World Conference
SUNRISE, Fla. , June 1, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella , will be presenti...
Source: PR Newswire
Date: June, 01 2018 08:00
USRM Chief Scientist Talks Stem Cell Journey, Autologous Stem Cells with 'Something Significant' Happy Living Podcast
SUNRISE, Fla. , May 17, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella , is featured in t...
Source: PR Newswire
Date: May, 17 2018 08:00
World Bodybuilding Expert Interviews USRM Chief Science Officer At Paleo F(X) Conference
SUNRISE, Fla. , May 15, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science Officer Dr. Kristin Comella's inter...
Source: PR Newswire
Date: May, 15 2018 08:00
Autologous Stem Cell Therapy May Hold Key to Regeneration
SUNRISE, Fla. , May 14, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science Officer Dr. Kristin Comell...
Source: PR Newswire
Date: May, 14 2018 08:00
USRM Chief Science Officer, Dr. Kristin Comella, Featured on Health Boot Camps' Webinar
SUNRISE, Fla. , May 10, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,  today announced its Chief Science Officer, Dr. Kristin Comella , is a ...
Source: PR Newswire
Date: May, 10 2018 08:00
U.S. Department of Justice Files Lawsuit at Request of FDA to Stop U.S. Stem Cell Clinic from Performing Autologous Stem Cell Procedure
SUNRISE, Fla. , May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its intention to vigorously defend a lawsuit filed today by the U....
Source: PR Newswire
Date: May, 09 2018 18:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.01910.01760.01910.016697,800
2018-12-130.018450.01830.019450.0183646,192
2018-12-120.01850.01920.01940.01823441,412
2018-12-110.01950.018550.01950.0181435,146
2018-12-100.0220.01950.0220.0166742,275

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14270,400697,80038.7504Short
2018-12-13411,965646,19263.7527Short
2018-12-12134,250441,41230.4138Cover
2018-12-11234,837435,14653.9674Short
2018-12-10409,734742,27555.1998Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on USRM.


About U.S. Stem Cell, Inc. (OTC: USRM)

Logo for U.S. Stem Cell, Inc. (OTC: USRM)

Founded in , U.S Stem Cell, Inc. is committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body s own healing potential, we may be able to reverse damaged tissue to normal function. U.S. Stem Cell s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. U.S Stem Cell is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.

 

 

 

Current Management

  • Miguel Tomas / President, CEO
  • Kristin Comella / CSO
  • Jill Arlene Robbins / Counsel
  • William P. Murphy Jr., M.D. / Chairman
  • Sheldon Anderson /
  • Mark P. Borman /

Current Share Structure

  • Market Cap: $21,314,651 - 03/16/2018
  • Authorized: 2,000,000,000 - 03/12/2018
  • Issue and Outstanding: 357,029,338 - 03/12/2018

 


Recent Filings from (OTC: USRM)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: May, 04 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 16 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 07 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 13 2017

 

 


Daily Technical Chart for (OTC: USRM)

Daily Technical Chart for (OTC: USRM)


Stay tuned for daily updates and more on (OTC: USRM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: USRM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in USRM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of USRM and does not buy, sell, or trade any shares of USRM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/